Fanconi Anemia Pathway Activation by FOXM1 is Critical to Bladder Cancer Recurrence and Anticancer Drug Resistance

被引:16
作者
Roh, Yun-Gil [1 ]
Mun, Jeong-Yeon [1 ]
Kim, Seon-Kyu [2 ,3 ]
Park, Won Young [4 ]
Jeong, Mi-So [1 ]
Kim, Tae Nam [5 ]
Kim, Won-Tae [1 ]
Choi, Yung Hyun [6 ]
Chu, In-Sun [3 ,7 ]
Leem, Sun-Hee [1 ]
机构
[1] Dong A Univ, Dept Biol Sci, Busan 49315, South Korea
[2] Korea Res Inst Biosci & Biotechnol KRIBB, Personalized Genom Med Res Ctr, Daejeon 34141, South Korea
[3] Korea Univ Sci & Technol, KRIBB Sch Biosci, Dept Bioinformat, Daejeon 34113, South Korea
[4] Pusan Natl Univ Hosp, Med Res Inst, Dept Pathol, Busan 49241, South Korea
[5] Pusan Natl Univ Hosp, Med Res Inst, Dept Urol, Busan 49241, South Korea
[6] Dong Eui Univ, Coll Korean Med, Dept Biochem, Busan 47227, South Korea
[7] Korea Res Inst Biosci & Biotechnol KRIBB, Genome Editing Res Ctr, Daejeon 34141, South Korea
基金
新加坡国家研究基金会;
关键词
bladder cancer; FOXM1; FANCD2; Fanconi anemia pathway; DNA repair; cancer recurrence; TRANSCRIPTION FACTOR FOXM1; FORKHEAD BOX M1; DNA-DAMAGE; MASTER REGULATOR; EXPRESSION; PROGRESSION; APOPTOSIS; CELLS; EPIDEMIOLOGY; GUIDELINES;
D O I
10.3390/cancers12061417
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although the 5-year survival rate of patients diagnosed with nonmuscle invasive bladder cancer (NMIBC) has reached 85%, more than 50% of patients suffer from frequent recurrences. To identify molecular targets associated with recurrence of NMIBC, we analyzed gene expression data and found that FOXM1 and FANCD2 were involved in recurrence. Therefore, we investigated how these genes were involved in the mechanism of recurrence and confirmed their usefulness as biomarkers. Investigation have shown that FOXM1 directly regulated the transcription of FANCD2, which is the key gene of the Fanconi anemia (FA) pathway. Depletion of FOXM1 resulted in DNA repair defects in the FA pathway and in decreased resistance to chemotherapy. Thus, the FANCD2-associated FA pathway activated by FOXM1 is an important mechanism involved in chemotherapy-related recurrence. In conclusion, FOXM1 and FANCD2 can be used as prognostic factors that are associated with high risk of recurrence and with anticancer drug resistance properties in NMIBC patients.
引用
收藏
页码:1 / 20
页数:19
相关论文
共 50 条
  • [21] PRRX1/FOXM1 reduces gemcitabin-induced cytotoxicity by regulating autophagy in bladder cancer
    Huang, Xixi
    Huang, Weiping
    Wu, Keming
    Lin, Qi
    Chen, Gang
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2022, 11 (08) : 1116 - +
  • [22] Nucleophosmin1 associated with drug resistance and recurrence of bladder cancer
    Huihui Hu
    Qian Meng
    Ting Lei
    Man Zhang
    Clinical and Experimental Medicine, 2015, 15 : 361 - 369
  • [23] CENPU affects the paclitaxel resistance of cervical cancer cells by regulating the FOXM1/ABCC5 pathway
    Zhang, Xia
    Zhang, Yuanyi
    Wang, Min
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2024, 45 (01) : 89 - 95
  • [24] FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin
    Li, Xiaoxiao
    Yao, Ruyong
    Yue, Lu
    Qiu, Wensheng
    Qi, Weiwei
    Liu, Shihai
    Yao, Yasai
    Liang, Jun
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2014, 18 (05) : 811 - 823
  • [25] FOXM1 predicts disease progression in non-muscle invasive bladder cancer
    Sebastien Rinaldetti
    Ralph Wirtz
    Thomas Stefan Worst
    Arndt Hartmann
    Johannes Breyer
    Lars Dyrskjot
    Philipp Erben
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 1701 - 1709
  • [26] Inactivation of the Akt/FOXM1 Signaling Pathway by Panobinostat Suppresses the Proliferation and Metastasis of Gastric Cancer Cells
    Lee, Na-Ri
    Kim, Da-Yeah
    Jin, Hua
    Meng, Ruoyu
    Chai, Ok Hee
    Kim, Seong-Hun
    Park, Byung-Hyun
    Kim, Soo Mi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (11)
  • [27] Inhibition of EZH2 and activation of ERRγ synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway
    Huang, Boyan
    Mu, Peiqiang
    Yu, Yan
    Zhu, Wenya
    Jiang, Tianqing
    Deng, Rong
    Feng, Gongkan
    Wen, Jikai
    Zhu, Xiaofeng
    Deng, Yiqun
    GASTRIC CANCER, 2021, 24 (01) : 72 - 84
  • [28] A novel FOXM1 isoform, FOXM1D, promotes epithelial-mesenchymal transition and metastasis through ROCKs activation in colorectal cancer
    Zhang, X.
    Zhang, L.
    Du, Y.
    Zheng, H.
    Zhang, P.
    Sun, Y.
    Wang, Y.
    Chen, J.
    Ding, P.
    Wang, N.
    Yang, C.
    Huang, T.
    Yao, X.
    Qiao, Q.
    Gu, H.
    Cai, G.
    Cai, S.
    Zhou, X.
    Hu, W.
    ONCOGENE, 2017, 36 (06) : 807 - 819
  • [29] The Anticancer Effects of FDI-6, a FOXM1 Inhibitor, on Triple Negative Breast Cancer
    Ulhaka, Karan
    Kanokwiroon, Kanyanatt
    Khongkow, Mattaka
    Bissanum, Rassanee
    Khunpitak, Thanaporn
    Khongkow, Pasarat
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (13)
  • [30] Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma.
    Yarde, Danielle N.
    Oliveira, Vasco
    Mathews, Linda
    Wang, Xingyu
    Villagra, Alejandro
    Boulware, David
    Shain, Kenneth H.
    Hazlehurst, Lori A.
    Alsina, Melissa
    Chen, Dung-Tsa
    Beg, Amer A.
    Dalton, William S.
    CANCER RESEARCH, 2009, 69 (24) : 9367 - 9375